ZGNX - Zogenix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
41.63
-0.30 (-0.72%)
At close: 4:00PM EDT

41.42 -0.21 (-0.50%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous Close41.93
Open41.90
Bid41.40 x 800
Ask47.00 x 800
Day's Range40.63 - 41.90
52 Week Range32.40 - 62.75
Volume258,501
Avg. Volume674,623
Market Cap1.741B
Beta (3Y Monthly)1.47
PE Ratio (TTM)N/A
EPS (TTM)-4.37
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est78.70
Trade prices are not sourced from all markets
  • Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners
    American City Business Journals2 days ago

    Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners

    A look at who's moving, who's growing and who's dealing in the Bay Area's health care and life sciences space.

  • GlobeNewswire16 days ago

    Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to three new non-executive employees. The awards were made on October 1, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company.  The inducement awards consist of options to purchase an aggregate of 22,700 shares of Zogenix common stock.  The options have a ten-year term and an exercise price equal to $46.74, the fair market value of Zogenix common stock on the date of grant.  The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter.

  • Is This the Biggest Threat to GW Pharmaceuticals' Marijuana Drug?
    Motley Fool20 days ago

    Is This the Biggest Threat to GW Pharmaceuticals' Marijuana Drug?

    The FDA and DEA have signed off on GW Pharmaceuticals' marijuana treatment for epilepsy, but its sales could stall if this other treatment nabs a regulatory OK.

  • GlobeNewswire23 days ago

    Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

    EMERYVILLE, Calif., Sept. 25, 2018-- Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of rare central nervous system disorders, today announced that Stephen J. Farr, Ph.D., ...

  • Is Pot Stock GW Pharmaceuticals Undervalued?
    Motley Fool27 days ago

    Is Pot Stock GW Pharmaceuticals Undervalued?

    The upcoming launch of its marijuana medicine for epilepsy could send sales surging.

  • Benzingalast month

    Zogenix Has $3.4B Opportunity With Pediatric Epilepsy Asset, BofA Says In Bullish Initiation

    Zogenix, Inc. (NASDAQ: ZGNX )'s lead asset ZX008 presents a multibillion-dollar opportunity, according to Bank of America Merrill Lynch. The Analyst Analyst Tazeen Ahmad initiated coverage of Zogenix with ...

  • Investors in This Top Marijuana Stock Can't Overlook These 2 Serious Challenges
    Motley Foollast month

    Investors in This Top Marijuana Stock Can't Overlook These 2 Serious Challenges

    Though this pot stock has been unstoppable for years, things may not stay that way for much longer.

  • TheStreet.comlast month

    Six Biotechnology Names on My Watch List

    The indices have been slowly drifting lower after a gap up open. Early breadth was around 3 to 1 positive but its now down to around 4-3 positive. The bulls are not producing much positive momentum but the bears are doing an even worse job of producing negative momentum.

  • Here's Why Zogenix Slipped 14.9% in August
    Motley Foollast month

    Here's Why Zogenix Slipped 14.9% in August

    The company announced and completed a share offering last month, but the timing worked out well.

  • TheStreet.comlast month

    Don't Dread a Market Correction, Think Opportunistically Instead

    Market corrections are too often feared by market players rather than embraced. The problem is that optimism tends to erode when there is a poor market and we are dealing with losses in individual stocks.

  • GlobeNewswirelast month

    Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to four new non-executive employees. The awards were made on September 1, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company.  The inducement awards consist of options to purchase an aggregate of 22,400 shares of Zogenix common stock.  The options have a ten-year term and an exercise price equal to $48.30, the fair market value of Zogenix common stock on the date of grant.  The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Zogenix

    NEW YORK, NY / ACCESSWIRE / September 4, 2018 / Major U.S. equities closed mostly higher on Friday and posted upbeat performance for the week. Market volatility source have been coming from U.S. and international ...

  • GlobeNewswirelast month

    Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that detailed results of the Phase 2, open-label study evaluating its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of refractory patients with Lennox-Gastaut Syndrome (LGS), were published in the September 2018 issue of Epilepsia. Consistent with the previously-reported data from this study, the results demonstrated that ZX008 provided sustained, clinically meaningful seizure reduction in the majority of patients and was generally well-tolerated.

  • GlobeNewswire2 months ago

    Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced new findings from multiple studies assessing the psychological and socioeconomic impact of epileptic encephalopathies, such as Dravet syndrome, in the United States and Europe. The first analysis found that siblings of children with epileptic encephalopathies may be at risk for anxiety or depression, with a significant proportion of both younger siblings and adult siblings reporting symptoms of anxiety and depressed mood.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Mallinckrodt Public and Zogenix

    NEW YORK, NY / ACCESSWIRE / August 17, 2018 / U.S. markets bounced back on Thursday after Walmart and Cisco reported upbeat quarterly earnings. The Dow Jones Industrial Average jumped 1.58 percent to close ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ZGNX earnings conference call or presentation 6-Aug-18 8:30pm GMT

    Q2 2018 Zogenix Inc Earnings Call

  • GlobeNewswire2 months ago

    Zogenix Prices Public Offering of Common Stock

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $52.00 per share. The gross proceeds to Zogenix from the offering, before underwriting discounts and commissions and offering costs, are expected to be $312,000,000.  Zogenix has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares to be sold in the offering are being sold by Zogenix.

  • Associated Press2 months ago

    Zogenix: 2Q Earnings Snapshot

    The Emeryville, California-based company said it had a loss of 83 cents per share. Losses, adjusted to account for discontinued operations, were 82 cents per share. The results beat Wall Street expectations. ...

  • GlobeNewswire2 months ago

    Zogenix Announces Proposed Public Offering of 6,000,000 Shares of Common Stock

    Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it intends to offer and sell, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering. Zogenix also expects to grant to the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock. All of the shares to be sold in the offering are to be sold by Zogenix.

  • GlobeNewswire2 months ago

    Zogenix Provides Corporate Update and Reports Second Quarter Financial Results

    Reported positive top-line results from second pivotal Phase 3 trial of ZX008 in patients with Dravet syndrome, Study 1504 Submission of U.S. and EU regulatory filings for ZX008 in Dravet syndrome anticipated ...

  • ACCESSWIRE2 months ago

    Zogenix, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Zogenix, Inc. (NASDAQ: ZGNX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. To listen ...

  • GlobeNewswire3 months ago

    Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    The awards were made on August 1, 2018 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix as an inducement to join the company.  The inducement awards consist of options to purchase an aggregate of 32,000 shares of Zogenix common stock.  The options have a ten-year term and an exercise price equal to $56.20, the fair market value of Zogenix common stock on the date of grant.  The options vest over a four-year period, with 25% of the options vesting on the first anniversary of each employee’s respective start date and the remainder vesting in equal monthly installments over the three years thereafter. The awards were approved by the independent compensation committee of Zogenix’s board of directors and were granted as an inducement material to the new employees entering into employment with Zogenix in accordance with Nasdaq Marketplace Rule 5635(c)(4).

  • GlobeNewswire3 months ago

    Zogenix to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 6

    EMERYVILLE, Calif., Aug. 01, 2018-- Zogenix, Inc., a pharmaceutical company developing therapies for the treatment of rare central nervous system disorders, today announced that it will report its financial ...

  • Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks
    MarketWatch3 months ago

    Tilray’s IPO is creating a buzz, but don’t overspend on marijuana stocks

    Valuations today are very high and sentiment is very positive — a bad combination, says Nigam Arora.

  • 3 Very Popular Marijuana Stocks on My "Do Not Buy" List
    Motley Fool3 months ago

    3 Very Popular Marijuana Stocks on My "Do Not Buy" List

    Not all pot stocks will have investors seeing green.